Reversing Liver Scarring, Not Just Fat: What the New Semaglutide Trial Data Show

For years, when we talked about weight-loss medications and the liver, the conversation stopped at fat. We could show that a drug reduced the amount of fat sitting inside liver cells, and that was genuinely good news. But many of my patients ask me a harder question: "Doctor, has the scarring already been done? Can anything actually undo it?" Until recently, I had to answer carefully, because we simply didn't have strong biopsy-based proof. That has now changed. New interim results from a Phase 3 trial called ESSENCE, testing semaglutide — the active ingredient in Ozempic and Wegovy — show that this medication can partially reverse liver scarring itself, not just shrink fat, and the evidence comes from actual liver biopsies, which remain the most reliable way to assess this disease.

Why Scarring, Not Fat, Is the Number That Matters Most

To understand why this trial is significant, it helps to separate two things that often get lumped together: fatty liver and liver scarring. Simple fatty liver is common and, on its own, often low-risk. But in some people, the fat triggers ongoing inflammation, and the liver responds to that injury the way it responds to any chronic injury — by laying down scar tissue, a process called fibrosis. When this inflamed, scarring form of the disease is confirmed on biopsy, we call it MASH (metabolic dysfunction-associated steatohepatitis), previously known as NASH. Fibrosis is staged from F0 (none) to F4 (cirrhosis, the most advanced and least reversible stage). Patients with F2 to F3 fibrosis have moderate-to-advanced scarring — serious, but one stage short of cirrhosis. Of everything we measure in MASH, fibrosis stage is the single strongest predictor of who will go on to develop cirrhosis, liver failure, or liver cancer. That is precisely why a treatment that can measurably improve fibrosis on biopsy is such important news — it targets the part of the disease that actually determines a patient's long-term outcome.

Inside the ESSENCE Trial

ESSENCE is a large, carefully designed Phase 3 trial that enrolled 1,197 adults, every one of whom had MASH confirmed by liver biopsy along with F2–F3 fibrosis. The typical participant was around 55 years old with a body mass index (BMI) of about 35 kg/m², over half had type 2 diabetes, and roughly two-thirds already had the more advanced F3-stage scarring — in other words, this was a population at real risk, not a mild or borderline group. Participants were randomly assigned, in a 2:1 ratio, to receive either once-weekly subcutaneous semaglutide 2.4 mg or placebo. The trial is designed to run a full 240 weeks, but the results I want to share with you come from a planned interim analysis at week 72, involving 800 of the enrolled participants. These interim findings were published in April 2026 in the journal Metabolism and Target Organ Damage, with the broader ESSENCE trial design and primary results also reported in the New England Journal of Medicine — two respected outlets, which gives me confidence in how rigorously this data has been reviewed.

The Results: Two Signals of Success on Biopsy

The trial measured two co-primary endpoints, both confirmed by repeat liver biopsy rather than blood tests or imaging alone, which is the gold-standard way to assess this disease. The first was MASH resolution without worsening of fibrosis — meaning the liver inflammation genuinely calmed down and the scarring didn't get worse in the process. About two-thirds of patients on semaglutide achieved this, compared with roughly one-third on placebo. The second, and to me the more striking result, was fibrosis improvement of at least one stage — real, biopsy-documented regression of scar tissue. About one-third of semaglutide-treated patients achieved this improvement, compared with about one-fifth of those on placebo. Alongside these liver-specific findings, patients on semaglutide lost about 10 to 11 percent of their body weight, versus about 2 percent with placebo, and also showed improvements in cardiometabolic markers, non-invasive blood-based fibrosis markers, and liver enzyme levels. The side-effect profile was consistent with what we already know about semaglutide from years of use in diabetes and obesity treatment — mostly gastrointestinal effects such as nausea, which tend to be manageable and often ease over time.

What This Means — and What It Doesn't

I want to be precise here, because I know how much hope numbers like these can create. This interim analysis is a major milestone: for the first time, we have biopsy-confirmed evidence that a widely available weight-loss medication can improve — not merely stall — established liver scarring. That is different, and more meaningful, than the fat-reduction data we already had. However, this is not a cure for cirrhosis. Everyone in this trial had F2–F3 fibrosis, which is scarring that occurs before cirrhosis develops; these results tell us nothing about reversing cirrhosis itself, which is a more advanced and generally far less reversible stage. It's also important to remember this is an interim look at 72 weeks out of a planned 240-week study — we still need the longer-term data to understand how durable these improvements are and whether they translate into fewer cases of liver failure or liver cancer over time. The trial continues, and I will be watching those later results closely.

Bottom Line

If you have been told you have MASH with moderate-to-advanced fibrosis, this trial offers real, biopsy-backed reason for optimism — evidence that treating the underlying metabolic disease with a medication like semaglutide can, in a meaningful proportion of patients, actually improve the scarring in your liver, not just the fat within it. But your liver disease is unique to you, your biopsy stage, your other health conditions, and your overall risk profile all matter in deciding what's right for you. Please don't start or stop any medication based on a trial summary alone. Bring this article to your next visit, and let's talk about where you stand and what options make sense for your liver health.